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The effect of cationic amphiphilic drugs (CAD) on the synthesis of thiol esters of coenzyme A with long- 
chain fatty acids was studied in microsomes of rat brain in vitro. The results indicate that propranolol, tetra- 
Caine and to a lesser extent, chloroquine, inhibit enzyme activity. Procaine and lidocaine did not inhibit 
enzyme activity in concentrations up to 0.8 mM. This inhibition seems to be directed primarily to the synthe- 
sis of polyunsaturated fatty acyl coenzyme A. The results also suggest that this inhibition may be due to 
the action of CAD on the microsomal membrane and not to an interaction of these drugs with the fatty 
acid substrates. 
Propranolol Tetracaine Chloroquine Arachidonic acid Docosahexanoic acid 
Long-chain acyl coenzyme A synthetase Local anesthetic 
1. INTRODUCTION 
Cationic amphiphilic drugs (CAD) alter the 
metabolism [l-9] and topology [lo] of 
phospholipids and cause functional impairment of 
excitable membranes. These drugs inhibit impulse 
conduction as a result of an effect on the sodium 
channel [ 1 l-131. Among the effects of CAD on 
membrane lipid metabolism is the redirecting of 
the de novo biosynthesis of glycerolipids by the in- 
hibition of phosphatidate phosphohydrolase 
[8,14-161. CAD also inhibit the activities of (a) 
acyl coenzyme A (CoA) : lysolecithin acyltransfer- 
ase of rat liver microsomes [17], (b) acyl-CoA: 
cholesterol acyl transferase of rat and rabbit arte- 
rial microsomes [l&20] and (c) phospholipase A 
from various sources [8,21-251. Several other 
steps in lipid metabolism also are affected, as has 
been shown in labeling studies with various tissues 
[5,8,26-301. However, there is no information 
about the effect of CAD on the formation of thiol 
esters of long-chain fatty acids with CoA. This 
reaction may play a role in the tenacious retention 
* To whom correspondence should be addressed 
of docosahexaenoic acid (22:6) by nervous tissue 
[31] and in limiting the availability of free ara- 
chidonic acid (20 : 4) for the formation of prostag- 
landins and lipoxygenase-leukotriene products 
[32]. The present investigations evaluated the ef- 
fect of propranolol, chloroquine and local anesthe- 
tics on the microsomal fatty acid-activating en- 
zyme system in rat brain in vitro using labeled 
palmitic acid (16 : O), 20 : 4 and 22 : 6 substrates. 
2. MATERIALS AND METHODS 
Male albino Wistar rats weighing 200-250 g 
were purchased from Harlan Sprague-Dawley, In- 
dianapolis, IN. Tetracaine HCl, procaine HCl, 
lidocaine and chloroquine diphosphate salt were 
purchased from Sigma, St Louis, MO. Pro- 
pranolol HCl was from Ayerst Labs, New York, 
NY. [ 1 -‘4C]Palmitic acid (54 mCi/mmol), all- 
cis-5,8,1 1,14-[l-‘4C]arachidonic acid (58 mCi/ 
mmol) and all-c&4,7,10,13,16, 19-[U-14C]do- 
cosahexaenoic acid (160 mCi/mmol) were pur- 
chased from New England Nuclear, Boston, MA. 
The sources of all other chemicals used in the pre- 
sent investigation have been given previously [31]. 
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Rats were decapitated, brains removed and 
homogenized, and microsomes were isolated as in 
[3 I]. Drugs were dissolved in 10 mM Tris-HCI buf- 
fer, pH 8.0, and added to the incubation system 
wherever needed. The fatty acid activation reac- 
tion has been described [31]. The assay mixture 
contained 30amol Tris-HCl (pH 8.0), 4pmoI 
MgC12, 500 nmol ATP, 200 nmol dithiothreitol, 
100 nmol CoA, 5 nmol labeled fatty acid and 
60-70 fig microsomal protein in a final volume of 
0.2 ml. The reaction was carried out for 5 min at 
37°C. One nmol of each fatty acid contained 
32000-43000 dpm. Protein content of micro- 
somes was estimated by the method of Lowry et al. 
[33] using crystalline bovine serum albumin as a 
standard . 
3. RESULTS AND DISCUSSION 
When brain microsomal fractions were prein- 
cubated with cationic amphiphilic drugs an inhibi- 
tion in the synthesis of CoA thiol esters of 16 : 0, 
20: 4 and 22: 6 was found. The inhibitory effect 
was concentration-dependent and propranolol was 
the most potent inhibitor, followed by tetracaine 
and chloroquine. Procaine and hdocaine did not 
inhibit fatty acid activation under comparable con- 
ditions up to 0.8 mM (fig.1). These two local 
anesthetics inhibited acyl transferase activity, but 
required 20-30-fold higher concentrations than 
that of tetracaine [171. Similar observations on the 
esterification of oleate to cholesterol have been 
made with rabbit aorta microsomes [IS,ZO]. 
The concentration of CAD required to inhibit 
the reaction by 50% varied with the substrate used 
(table 1). The amount of propranolol needed was 
much lower than that of tetracaine or chloroquine. 
The activation of polyunsaturated fatty acids, 
especially arachidonic acid, seems to be more 
susceptible to CAD than palmitic acid except for 
chloroquine. 
Studies were extended to evaluate the 
mechanism by which CAD inhibits the fatty acid 
activation enzyme system (table 2). When the 
drugs were added (100-400 fcM) to the incubation 
medium prior to the onset of the reaction, there 
wa$%o inhibition in thiol ester formation. Similar 
results were obtained when the drugs were prein- 
cubated with fatty acids (table 2). However, there 
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Fig. 1. Effect of varying amounts of CAD on the fatty 
acid activating enzyme system from rat brain 
microsomal membrane. Different concentrations of 
drug were preincubated with 60-7Opg microsomal 
membrane protein at 37°C for 5 min; control tubes were 
preincubated with buffer. After this preincubation, the 
mixture of assay ingredients was added and incubated 
5 min at 37°C. The reaction was terminated and the 
labeled fatty acyl CoA formed was extracted and 
assayed as described previously [32]. Each value 
represents mean + SE of at least 6 incubations carried 
out at two or three different times with the various 
microsomal preparations. Details of the assay system are 
described in section 2. The mean + SE of control values 
(nmol/min per mg protein) obtained for the fatty acid 
activating enzyme system with labeled paimitate, 
arachidonate and docosahexaenoate were 5.6 + 0.18 
(n = 8), 5.93 k 0.12 (n = 10) and 1.93 rt 0.05 (n = 8), 
respectively. 
was a significant inhibition when microsomes were 
preincubated with the drugs. These results suggest 
that (a) preincubation of the drug with microsomal 
fraction is necessary to inhibit fatty acid activation 
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Table 1 
Concentration of cationic amphiphilic drugs required to 
produce 50% inhibition in microsomal fatty acid 
activation 
Drug Fatty acid bM) 
16:0 20:4 22:6 
Number of 
observations 8 10 8 
Propranolol 71 + 2.1 35 + 1.5 45 + 2.4 
Tetracaine 159 + 4.2 70 + 1.2 102 f 2.8 
Chloroquine 93 + 3.2 117 + 4.4 142 I!I 4.8 
Details of the assay system and other conditions are 
described in section 2. The values were calculated from 
data in fig.1 
acid activation enzyme system by disrupting the 
membrane structure and thereby inactivating the 
enzyme and/or by interacting with the active site 
of the enzyme. The various drug concentrations 
needed to produce a 50% inhibition of enzyme ac- 
tivity with the different fatty acid substrates used 
suggest hat both of the above possibilities may be 
involved in this inhibition. 
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Table 2 
Effect of cationic amphiphilic drugs on fatty acid activation in rat brain microsomes 
Pre- Incubation 
incubation (5 min) 
(5 min) 
None Complete assay 
mixture plus 
drug 
Fatty acid Addition of 
plus drug other com- 
ponents of 
assay mixture 
Microsomes Addition of 
plus drug other com- 
ponents of 
assay mixture 
Controla 
16:O 20:4 
7.8k 9.5 f 
0.19 0.17 
7.7 + 9.4* 
0.14 0.20 
5.5* 5.4* 
0.10 0.13 
Drugsb 
Propranolol Tetracaine Chloroquine 
1OOpM 200 ,uM 200 ItM 400 pM 
16:0 20:4 20:4 16:0 20~4 16:0 20:4 
97* 99+ 102-t 96+ 99+ 97k 99* 
1.5 2.2 2.4 1.7 2.2 1.4 2.4 
98+ 96+ 102* lOO+ 99* 103+ 102* 
1.1 1.6 3.3 2.3 1.1 2.0 3.9 
40* 16k 5.4k 40* 2.4k 24k 8k 
0.7 0.3 1.4 1.0 0.6 0.5 1.0 
a Values expressed as nmol/min per mg protein and are mean + SE, n = 6-8 
b Values expressed as % control and are mean f SE, n = 6-8 
Details of assay system and other conditions are described in section 2 
and (b) there is no drug effect on the membrane 
when these drugs are added in the presence of 
other assay components (perhaps because of the 
protective effects of one or more of the assay mix- 
ture components). 
These results suggest hat CAD inhibit the fatty 
REFERENCES 
[l] Bazan, N.G., Illincheta de Boschero, M.G., 
Giusto, N.M. and Bazan, H.E.P. (1976) Adv. Exp. 
Med. Biol. 72, 139-148. 
[2] Bazan, N.G. (1982) Vis. Res. 22, 1539-1542. 
113 
Volume 182, number 1 FEBS LETTERS March 1985 
[3] Abdel-Latif, A.A. and Smith, J.P. (1976) 
Biochem. Pharmacol. 25, 1697-1704. 
[4] Brindley, D.N. and Bowley, M. (1975) Biochem. J. 
148, 461-469. 
[S] Eichberg, J. and Hauser, G. (1974) Biochem. Bio- 
phys. Res. Commun. 60, 1460-1467, 
[6] Eichberg, J., Gates, J. and Hauser, G. (1979) Bio- 
chim. Biophys. Acta 573, 90-106. 
[7] Hauser, G. and Eichberg, J. (1975) J. Biol. Chem. 
250, 105-110. 
[S] Hauser, G. and Pappu, AS. (1982) in: 
Phospholipid Metabolism in the Nervous System 
(Horrocks, L.A. et al. eds) pp.283-300, Raven, 
New York. 
[9] Illincheta de Boschero, M.G. and Bazan, N.G. 
(1982) Biochem. Pharmacol. 31, 1049-1055. 
[lo] Bradford, P.G. and Marinetti, G.V. (1982) J. 
Membrane Biol. 67, 221-218. 
[ll] Lee, A.G. (1976) Nature 262, 545-548. 
1121 Courtney, K. (1980) J. Pharmacol. Exp. Ther. 213, 
114-119. 
[13] Huang, L. and Ehrenstein, G. (1981) J. Gen. 
Physiol. 77, 137-153. 
[ 141 Bowely, M., Cooling, J., Burditt, S.L. and 
Brindley, D.N. (1977) Biochem. J. 165, 447-454. 
(151 Sturton, R.G. and Brindiey, D.N. (1980) Biochim. 
Biophys. Acta 619, 494-505. 
[16] Eichberg, J,, Gates, J. and Hauser, G. (1979) Bio- 
chim. Biophys. Acta 573, 90-106. 
[17] Shier, W.T. (1977) Biochem. Biophys. Res. Com- 
mun. 75, 186-193. 
[18] Bell, F.P. and Hubert, E.V. (1981) Atherosclerosis 
39, 517-525. 
[19] Bell, F.P. (1981) Atherosclerosis 38, 81-88. 
1201 Bell, F.P. (1983) Exp. Mol. Pathol. 38, 336-345. 
[21] Seppala, A.J., Saris, N.E.L. and Gauffin, M.L. 
(1971) Biochem. Pharmacol. 20, 305-313. 
1221 Scherphof, G.L., Scarpa, A. and Van 
Toorenenbergen, A. (1972) Biochim. Biophys. 
Acta 270, 226-240. 
[23] Waite, M. and Sissian, P. (1972) Biochemistry 11, 
3098-3105. 
[24] Kunze, H., Bohm, E, and Vogt, W. (1974) Bio- 
chim. Biophys. Acta 360, 260-269. 
12.51 Scherphof, G. and Westenberg, H. (1975) Biochim. 
Biophys. Acta 398, 442-451. 
[26] Brindley, D.N., Allan, D. and Mitchell, R.H. 
(1975) J. Pharm. Pharmacol. 27, 462-464. 
1271 Bazan, H.E.P., Careaga, M.M. and Bazan, N.G. 
(1981) Biochim. Biophys. Acta 666, 63-71. 
1281 Abdel-Latif, A.A., Smith, J.P. and Akhtar, R.A. 
(1983) Biochem. Pharmacol. 32, 3815-3821. 
[29] Blohm, T.R. (1979) Pharm. Rev. 30, 593-603. 
[30] Franson, CR., Pang, D.C. and Weglicki, W.B. 
(1979) Biochem. Biophys. Res. Commun. 90, 
956-962. 
[31] Reddy, T.S., Sprecher, H. and Bazan, N.G. (1984) 
Eur. J. Biochem. 145, 21-29. 
[32] Reddy, T.S. and Bazan, N.G. (1983) Arch. Bio- 
them. Biophys. 226, 125-133. 
[33] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and 
Randall, R.J. (1951) J. Biol. Chem. 193, 265-275. 
114 
